(no title)
gnodar | 6 years ago
Misleading. The agency, in this case NSF, obtains march in rights for patents (not data) developed using funds received from them. They will only exercise that right in the most extraordinary circumstance. Basically, if you develop a cure to cancer and then decide not to commercialize it or make it publicly available, they may exercise march in rights and take it over. No agency, not even the DoD, has ever exercised it, to my knowledge.
No comments yet.